Hepatitis B Vaccines

被引:126
作者
Pattyn, Jade [1 ]
Hendrickx, Greet [1 ]
Vorsters, Alex [1 ]
Van Damme, Pierre [1 ]
机构
[1] Univ Antwerp, Ctr Evaluat Vaccinat, Antwerp, Belgium
关键词
hepatitis B virus; hepatitis B; hepatitis B vaccination; VIRUS; IMMUNIZATION; ANTIGEN;
D O I
10.1093/infdis/jiaa668
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality. Affordable, safe, and effective, hepatitis B vaccines are the best tools we have to control and prevent hepatitis B. In 2019, coverage of 3 doses of the hepatitis B vaccine reached 85% worldwide compared to around 30% in 2000. The effective implementation of hepatitis B vaccination programs has resulted in a substantial decrease in the HBV carrier rate and hepatitis B-related morbidity and mortality. This article summarizes the great triumphs of the hepatitis B vaccine, the first anticancer and virus-like-particle-based vaccine. In addition, existing unresolved issues and future perspectives on hepatitis B vaccination required for global prevention of HBV infection are discussed.
引用
收藏
页码:S343 / S351
页数:9
相关论文
共 15 条
  • [1] Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000)
    Beutels, P
    [J]. HEALTH ECONOMICS, 2001, 10 (08) : 751 - 774
  • [2] A NEW ANTIGEN IN LEUKEMIA SERA
    BLUMBERG, BS
    ALTER, HJ
    VISNICH, S
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 191 (07): : 541 - &
  • [3] DANE DS, 1970, LANCET, V1, P695
  • [4] THE INFLUENCE OF AGE ON THE DEVELOPMENT OF THE HEPATITIS-B CARRIER STATE
    EDMUNDS, WJ
    MEDLEY, GF
    NOKES, DJ
    HALL, AJ
    WHITTLE, HC
    [J]. PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 1993, 253 (1337) : 197 - 201
  • [5] THE SAFETY OF THE HEPATITIS-B VACCINE - INACTIVATION OF THE AIDS VIRUS DURING ROUTINE VACCINE MANUFACTURE
    FRANCIS, DP
    FEORINO, PM
    MCDOUGAL, S
    WARFIELD, D
    GETCHELL, J
    CABRADILLA, C
    TONG, M
    MILLER, WJ
    SCHULTZ, LD
    BAILEY, FJ
    MCALEER, WJ
    SCOLNICK, EM
    ELLIS, RW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (07): : 869 - 872
  • [6] CHRONIC HEPATITIS-B
    HOOFNAGLE, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (05) : 337 - 339
  • [7] What level of hepatitis B antibody is protective?
    Jack, AD
    Hall, AJ
    Maine, N
    Mendy, M
    Whittle, HC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (02) : 489 - 492
  • [8] Global status of hepatitis B immunisation
    Kane, MA
    [J]. LANCET, 1996, 348 (9029) : 696 - 696
  • [9] Hepatitis B and the Need for a Booster Dose
    Leuridan, Elke
    Van Damme, Pierre
    [J]. CLINICAL INFECTIOUS DISEASES, 2011, 53 (01) : 68 - 75
  • [10] Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1